Amgen packs up in Claudin6
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
ESMO 2023 – tarlatamab hits the target for Amgen
But late-breaking data raise questions about lack of a dose response.
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
But late-breaking data raise questions about lack of a dose response.
